MedTrace Logo

Comparative Study on Postoperative Analgesia With Transversus Abdominis Plane Block to Local Anesthetic Infiltration With Ropivacaine in Laparoscopic Abdominal Surgery

NCT05995301 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-08-28

No results posted yet for this study

Summary

The goal of this clinical trial is to compare the postoperative analgesic efficacy of ultrasound-guided TAP block with Local Anesthetic Infiltration of ropivacaine in patients undergoing laparoscopic surgery. The main question it aims to answer is:

• If Transversus Abdominis Plane block with Ropivacaine will produce long duration of analgesia than the Local Anesthetic Infiltration with ropivacaine after laparoscopic abdominal surgery .

Conditions

  • Analgesia
  • Ropivacaine
  • Laparoscopic Abdominal Surgery
  • Local Infiltration

Interventions

DRUG

Ropivacaine in Transversus abdominis plane

This group received 20ml of Ropivacaine 0.2% Injectable Solution in bilateral transversus abdominis plane at the end of surgery

DRUG

Ropivacaine in Local infiltration at port site

This group received local infiltration of 20ml of Ropivacaine 0.2% Injectable Solutionat port sites at the end of surgery

Sponsors & Collaborators

  • National Academy of Medical Sciences, Nepal

    lead OTHER_GOV

Principal Investigators

  • Surendra Bhusal, MD · NAMS Bir Hospital

  • Brihaspati K C, MD · NAMS Bir Hospital

  • Kaushal Tamang, MD · NAMS Bir Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-12
Primary Completion
2022-11-12
Completion
2023-02-25

Countries

  • Nepal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05995301 on ClinicalTrials.gov